A new group of derivatives of salicylic acid containing NO-donor furoxans, and the related des-NO-furazans, were synthesized and evaluated as new aspirin-like molecules. Their stability was assessed in acid (pH 1) and physiological solutions (pH 7.4), and in human serum. No compound exhibited COX-inhibitory activity against COX-1 and COX-2 isoforms, when tested up to 100 lM, respectively, on isolated platelets and on monocytes. Phenylsulfonyl-and cyano-substituted furoxans inhibited platelet aggregation induced by collagen in human platelet-rich plasma, through a cGMP dependent mechanism. Furoxan derivatives displayed cGMP-dependent vasodilator activities, tested on rat aorta strips precontracted with phenylephrine. All products showed antiinflammatory activity similar to that of ASA, tested on rats by the carrageenan-induced paw edema assay. Unlike ASA, all products showed markedly reduced gastrotoxicity in a rat lesion model.
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Introduction
The major limitation on the prolonged use of aspirin (ASA) 1 ( Fig. 1 ) is its gastrotoxicity, responsible for gastric ulceration, exacerbation of peptic ulcer symptoms, gastrointestinal hemorrhage, erosive gastritis, delay in ulcer healing and, in some cases, death.
into the mucosal cell, with consequent trapping of hydrogen ions, or both. These events principally depend on the product's pKa and lipophilicity. The systemic mechanisms are mainly related to the drug's ability to inhibit the COX-1 enzyme present in gastric epithelial cells, and consequently to block the production of prostaglandins, known to be crucial in defending the gastric mucosa. In view of the gastrosparing and anti-inflammatory actions exerted by nitric oxide (NO), 12, 13 one of the strategies proposed to overcome the problem of ASA's gastrotoxicity is that of linking the drug with an appropriate NO-donor moiety. Most such products are obtained by linking the NO-donor moieties to the carboxylic site of aspirin through an ester linkage (Fig. 1A ). [14] [15] [16] [17] Recently, we proposed a new class of NO-donor aspirin-like molecules obtained by substituting the acetyl group of aspirin with acyl groups, containing nitrooxy NO-donor moieties (Fig. 1B) . 18 In order to explore the influence exerted by the nature of the NO-donor moiety on the pharmacological profile of this new type of products, we here describe the synthesis and pharmacological activity of a new class of compounds, obtained by substituting acyl groups containing NO-donor furoxan moieties for acetyl group of ASA (compounds 13, 14, 17 and 18, Fig. 2 ). Furoxans are NO-donors able to release NO through a mechanism different from that occurring for the organic esters of nitric acid. It is generally accepted that they can produce NO under the action of thiol cofactors, 19 while nitrooxy derivatives require principally enzymatic metabolism. 20 This new class of products might be expected to display a pharmacological profile different from that observed for the nitrooxy analogues, 21 in the light of both the different structure and the different NO-release mechanism of acylation. Conversely a number of nitrooxyacyl derivatives of salicylic acid, previously described by our group, were shown to be potent irreversible inhibitors of both enzymes.
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Platelet anti-aggregatory activity
Both the furoxan and the furazan series were studied for their action on collagen-induced platelet aggregation of human platelet-rich plasma. The results, expressed as IC 50 , or as percentage of
inhibition at the highest concentration tested when IC 50 could not be calculated, are reported in Table 2 . The data show that the furazan derivatives display either no activity or very weak activity.
The only exception is the amide compound 17a, which displays low antiaggregatory action. This activity was shown to be due to abundant NO-release in the platelets, following the synergistic effect of high intracellular concentrations of glutathione (GSH) and ascorbate in these kind of cells. 22 The furoxan amide compound 17 acts as a rather good antiaggregatory agent; however, its antiplatelet activity was found not to be influenced by the presence of ODQ, suggesting that NO dependent sGC activation plays little or no role in this action. As in the case of the related furazancarboxyamide 17a, an antiaggregatory mechanism that is neither COX-nor NO-dependent must be involved. Indeed, preliminary results obtained with these two products indicate that they behave as antagonists at the thromboxane receptor (IC 50 (CL 95%)0 M: 38 (37-38) and 39 (37-42) for compound 17 and 17a, respectively). The above picture indicates that the potential value of this new series of furoxanylacyl derivatives of salicylic acid as anti-thrombotic agents is limited, since none of these compounds act as irreversible inhibitors of the COX-enzymes, unlike aspirin and some its nitrooxyacyl analogues.
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Vasodilator activity
The vasodilatory effects of the furoxan derivatives were evaluated on endothelium-denuded rat aorta strips, pre-contracted with phenylephrine. All the furoxan products were capable of relaxing the contracted tissue in a concentration-dependent manner. The vasodilator potencies, expressed as EC 50 , are shown in 24 whose substructure is present in 14. Both these two products were found to be devoid of tolerance development.
Anti-inflammatory activity
All products in the furoxan and furazan series were tested on carrageenan-induced paw edema in conscious rats, together with aspirin (ASA) and salicylic acid. Injection of carrageenan into the rat's hind paw produced immediate swelling, which peaked at 4-5 h. Aspirin, administered by the intragastric route at 120 mg/kg just prior to carrageenan injection, significantly reduced (43.0 ± 3.3%) paw edema at 3 h, compared to vehicle-treated animals ( Table 2 ). Salicylic acid acted similarly, reducing paw edema by 37%. The furoxan products significantly inhibited paw edema, from 37% to 55%, when administered intragastrically at doses equimolar with aspirin 120 mg/kg ( Table 2 ). The most efficacious inhibitors were the phenylsulfonyl-and cyano-substituted furoxans 14 and 18, for which inhibition reached 50% and 55%, respectively. Either the NO released by the products, 25 and/or the salicylic acid deriving from their metabolic transformation, could be involved in this activity. 26 The finding that the des-NO furazan analogues also displayed potent antiinflammatory action (about 40% inhibition) appears to minimize the role played by NO in the observed effects, suggesting conversely that salicylic acid plays a paramount role. Indeed, both salicylic acid and the present series of compounds are ineffective as inhibitors of prostanoid synthesis under in vitro conditions, while being as effective as aspirin in inhibiting the rat paw edema. As for the mechanism involved, it has been proposed that the inhibition of COX-2 enzyme induction (via inhibition of NFkB signaling) may represent the major mode of action of salicylates in vivo. 26 Conversely, in some of the previously-described nitrooxy analogues, COX-acylation might also contribute to their in vivo anti-inflammatory activity.
Acute gastric mucosal damage
All compounds, including aspirin and salicylic acid as reference standards, were assessed for their ulcerogenic properties in conscious rats. The development of gastric lesions was assessed 3 h after intragastric administration of the compounds, and lesions were quantified by determining the 'lesion index' on the basis of their greatest length in millimeters ( Table 2 ). In the present study aspirin, administered at 120 mg/kg, produced macroscopically detectable gastric damage, characterized by mucosal necrosis and hemorrhage (lesion index = 50 ± 3.8).
By contrast salicylic acid, tested under the same conditions, showed much lower gastrotoxicity, in keeping with findings that it lacks this side effect in experimental animals. 26 All the NO-donor products, as well as their des-NO furazan analogues, also displayed greatly reduced gastrotoxicity when administered at doses equimolar with aspirin. In the light of the fact that the products are not COX-inhibitors, and of the finding that the des-NO furazan analogues are devoid of gastrotoxicity (Table 2) , a possible explanation for this finding is that they behave in vivo essentially as pro-drugs of salicylic acid. By contrast, in the COX-inhibitor nitrooxyacyl analogues, a role of NO in the reduced gastrotoxicity must be considered.
Conclusions
A new series of salicylic acid derivatives, containing NO-donor furoxan moieties linked to the hydroxyl group through an ester bridge, were designed together with the corresponding des-NO furazan analogues. The furoxan derivatives display antiaggregatory, vasodilator and antiinflammatory properties, and show very limited gastrotoxicity when tested in conscious rats. The mechanisms responsible for these properties are somewhat different from those of the nitrooxy analogues previously described, due to both the different structure and the different NO-release mode of the respective NO-donor moieties. In particular in this new series of compounds, the antiaggregatory activity is dependent on the thiol-induced NO-release by furoxan moieties in platelets and the products are unable to inhibit COX-enzyme. The comparison with the corresponding des-NO furazans indicates that salicylic acid formed following hydrolysis under the action of serum esterases, is the main responsible of the anti-inflammatory activity of the series.
The designed products are an emblematic example of how the appropriate selection of the NOreleasing group is a critical aspect in designing NO-hybrid compounds.
Experimental section
Chemistry 1 H and 13 C NMR spectra were recorded on a Bruker Avance 300 at 300 and 75 MHz, respectively, using TMS as internal standard. Low resolution mass spectra were recorded with a Finnigan-Mat TSQ-700. Melting points were determined with a capillary apparatus (Büchi 540 CAS1609 was a gift from Sanofi-Aventis Deutschland GmbH.
General procedure for the preparation of 4, 4a and 5a
A solution of Jones reagent 2.5 M (19 mL, 46.62 mmol) was added to a stirred solution of the appropriate alcohol (18.65 mmol) in acetone (150 mL), cooled at 0 °C. The mixture was allowed to reach rt and stirred for 4 h. iPrOH (10 mL) was added and the mixture was concentrated under reduced pressure. The residue was dissolved in EtOAc (150 mL) and extracted with a saturated solution of NaHCO 3 (3 x 20 mL). The aqueous layers were acidified with 6 M HCl and extracted twice with EtOAc (50 mL). The combined organic layers were dried and concentrated under reduced pressure to give the desired compound. 
3-(3-Phenylfuroxan-4-yloxy)propanoic acid (4)
.
Methyl 2-[(3-aminocarbonylfuroxan-4-yl)methyl]thioacetic acid (7).
To a solution of 4-bromomethylfuroxan-3-carboxyamide (3.1 g, 14 mmol) in CH 3 CN (100 mL) 
General procedure for the preparation of 9 and 9a
To a solution of the appropriate amide derivative (0. General procedure for the preparation of 8, 8a, 10 and 10a
To a solution of the appropriate methyl ester (6.3 mmol) in dioxane (30 mL), 6 M HCl (30 mL) was added and the mixture heated at 70 °C for 4 h. After concentration under reduced pressure, the residue was dissolved in EtOAc (30 mL) and the solution washed with H 2 O (50 mL), and extracted twice with a saturated solution of NaHCO 3 (30 mL). The aqueous layers were acidified and extracted twice with EtOAc (30 mL). The organic layers were washed with brine (50 mL), dried and concentrated under reduced pressure to give the desired product. General procedure for the preparation of 13, 13a, 14 and 14a. nm, injection 4 mL, solution 51 mg/mL) to give the desired compound. under N 2 at 0 °C. The mixture was allowed to reach rt and then stirred overnight. The mixture was washed twice with 2 M HCl (20 mL). The combined organic layers were dried and concentrated under reduced pressure. The crude product was purified as follows. 
2-[(3-Aminocarbonylfuroxan-4-yl)methyl]thioacetic acid (8
2-[(4-Aminocarbonylfurazan-3-yl)methyl]thioacetic acid (8a
2-[(4-Cyanofurazan-3-yl)methyl]thioacetic acid (10a
2-({3-[(3-Phenylfuroxan-4-yl)oxy]propanoyl}oxy)benzoic acid (13
2-({3-[(4-Phenylfurazan-3-yl)oxy]propanoyl}oxy)benzoic acid (13a
2-[(3-{[(4-Phenylsulfonyl)furazan-3-yl]oxy}propanoyl)oxy]benzoic acid (14a
2-{[(3-Aminocarbonylfuroxan-4-yl)methyl]thioacetoxy}benzoic acid (17
2-{[(4-Aminocarbonylfurazan-3-yl)methyl]thioacetoxy}benzoic acid (17a
Stability studies Evaluation of stability in aqueous buffered solutions
A solution of each compound (10 mM) in acetonitrile was added to HCl 0.1 M or to phosphate buffer pH 7.4 (50 mM) preheated at 37 °C; the final concentration of the compound was 100 M.
The resulting solution was maintained at 37 ± 0.5 °C and, at appropriate time intervals, a 20 L aliquot of reaction solution was analyzed by RP-HPLC, as described below.
Stability in human serum
A solution of each compound (10 mM) in acetonitrile was added to human serum (Sigma) preheated to 37 °C; the final concentration of the compound was 200 M. The resulting solution was incubated at 37 ± 0.5 °C and, at appropriate time intervals, 300 L of reaction mixture were withdrawn and added to 300 L of acetonitrile containing 0.1% trifluoroacetic acid, in order to deproteinize the serum. The sample was sonicated, vortexed and then centrifuged for 10 min at 2150 g, the clear supernatant was filtered through 0.45 m PTFE filters (Alltech) and analyzed by RP-HPLC The reverse-phase HPLC procedure separated and quantitated the remaining compound and salicylic acid. HPLC analyses were performed with a HP 1100 chromatograph system (Agilent Technologies, Palo Alto, CA, USA) equipped with a quaternary pump (model G1311A), a membrane degasser (G1379A), and a diode-array detector (DAD) (model G1315B) integrated in the HP1100 system. Data analysis was done by the HP ChemStation system (Agilent Technologies).
The analytical column was a Nucleosil 100-5C18 Nautilus (250 x 4.6 mm, 5 m particle size) and humidity (60 ± 5%), with an artificial 12:12 h light/dark cycle. They were deprived of food but not of water 24 h before the experiments. Groups of rats (n = 8-10) were given aspirin 120 mg kg -1 by intragastric route or equimolar doses of the compounds under study (vehicle CMC 1%). Rats were sacrificed 3 h after the administration of the compounds. Immediately after the sacrifice, the stomachs were removed, opened along the lesser curvature and examined for the assessment of mucosal lesions. The stomachs were laid on a flat surface under a stereomicroscope. The glandular mucosa was examined and each individual hemorrhagic lesion was measured along its greatest length (<1 mm: rating = 1; 1-2 mm: rating = 2; >2 mm: rating according to their greatest length).
The lengths of the lesions were summed to give an overall total, designated as the lesion index, for each stomach. The results obtained are presented as mean ± SEM. Statistical analysis was performed with ANOVA followed by Newman-Keuls test.
Inhibition of human platelet aggregation in vitro
Venous blood samples were obtained from healthy volunteers who had not taken any drug for at least two weeks. Volunteers, who were treated according to Helsinki protocol for biomedical experimentation, gave their informed consent to the use of blood samples for research purposes. 
COX-1 inhibition
In order to evaluate COX-1 inhibitory activity, washed platelets from individual donors were prepared as described elsewhere. 18 Aliquots of platelets (200 L at 108 cells mL -1 ) were incubated with inhibitors at different concentrations (diluted from 400-fold concentrated solutions in DMSO)
for 30 min at 37 °C, before addition of calcium ionophore (A23187, 2 M). After 10 min at 37 °C, the reactions were terminated with 100 L of methanol. TXB 2 in the supernatant was determined by enzyme immunoassay (Cayman Chemical). Percent inhibition of TXB 2 production in compoundtreated samples was calculated by comparison with untreated control samples. Background (no ionophore) TXB 2 production was subtracted from each value obtained in the presence of ionophore.
COX-2 inhibition
In order to evaluate COX-2 inhibitory activity, human monocytes were isolated from buffy coats obtained from the SIMT (Banca del sangue, AOU San Giovanni Battista Hospital, Turin, Italy).
Mononuclear cells were isolated as described elsewhere. 18 The monocytes (106 cells mL -1 were incubated with LPS (10 g mL -1 ) for 18 h at 37 °C in a 5% CO 2 atmosphere. Aliquots of LPSstimulated monocytes were centrifuged (300g, 8 min) and resuspended in fresh FCS-free RPMI-1640 medium. Each compound (diluted from 200-fold concentrated solutions in DMSO) was added at different concentrations to the monocyte suspensions; the aliquots of monocytes were then incubated at 37 °C in a 5% CO 2 atmosphere for 30 min, prior to stimulation with arachidonic acid (100 M) for 15 min. Cell suspensions were centrifuged and cell-free supernatants were stored at -20 °C until eicosanoid determination was completed. PGE 2 in the supernatant was determined by EIA (Cayman Chemical). Percent inhibition of PGE 2 production in compound-treated samples was calculated versus untreated control samples. Background (no arachidonic acid) PGE 2 production was subtracted from each value obtained in the presence of arachidonic acid.
